Management of Bethesda III (AUS/FLUS) Thyroid Nodules
For Bethesda III thyroid nodules, management should be stratified based on nuclear atypia and ultrasound features: nodules with nuclear atypia AND high-risk sonographic features warrant diagnostic hemithyroidectomy, while those with architectural atypia alone and low-risk ultrasound can be managed with repeat FNA or active surveillance.
Risk Stratification Framework
The 2022 French consensus guidelines 1 establish that Bethesda III should be used as a "last resort" category, not as a catch-all. The critical insight from recent research is that not all Bethesda III nodules carry equal malignancy risk—the overall malignancy rate ranges from 20-50% depending on cytomorphologic subtype and imaging features 2, 3, 4.
Cytomorphologic Subclassification
The most important prognostic factor is the type of atypia present:
- Nuclear atypia: Carries the highest malignancy risk at 59-68% 2, 4
- Architectural atypia: Lower risk at 32% 4
- Oncocytic atypia: Intermediate risk
- Cystic/inflammatory atypia: Lower risk
Nuclear atypia is an independent predictor of malignancy (OR 13.3 in one study 5, OR 4.52 in another 4) and should trigger more aggressive management.
Ultrasound Integration
Combining cytology with sonographic risk stratification significantly improves decision-making 2, 6:
- High-risk ultrasound features (ATA high suspicion, ACR TI-RADS 5, EU-TIRADS high risk, marked hypoechogenicity, punctate echogenic foci, irregular margins) increase malignancy risk from 6-10% to 59-75% when nuclear atypia is present 2
- ATA intermediate and high-risk patterns are independent predictors of malignancy (OR 1.57 and 3.92 respectively) 6
Management Algorithm
For Nodules WITH Nuclear Atypia:
- If high-risk ultrasound features present: Proceed directly to diagnostic hemithyroidectomy 2, 3
- If intermediate-risk ultrasound: Consider molecular testing if available 7, otherwise proceed to surgery given the 55-60% malignancy risk 3
- If low-risk ultrasound: Molecular testing or close surveillance with repeat FNA
For Nodules WITHOUT Nuclear Atypia (Architectural/Other):
- Repeat FNA after >3 months (NOT earlier—delayed repeat FNA is 2.5 times more likely to achieve diagnostic resolution than early repeat) 8
- Consider core needle biopsy if repeat FNA needed—CNB has significantly lower inconclusive rates (17.6%) compared to repeat FNA (37.3%) 9
- Active surveillance is appropriate for low-risk ultrasound nodules, with 95.8% remaining stable at 24+ months 3
Molecular Testing Considerations
The 2022 French guidelines 7 acknowledge molecular testing as an emerging tool for indeterminate nodules, though cost ($3,000-6,000) and availability limit widespread use. When available, molecular testing can help avoid unnecessary surgery in the 60-70% of Bethesda III nodules that are ultimately benign.
Clinical Outcomes and Prognosis
Important reassurance for patients: Even when malignancy is confirmed in Bethesda III nodules, 95.7% are low-risk differentiated thyroid cancers 3, with excellent long-term outcomes (5-year disease-free survival 95.3%, disease-specific survival 97.9%) 3. The predominant malignant histologies are papillary thyroid carcinoma (55%) and follicular thyroid carcinoma (37%) 5.
Key Pitfalls to Avoid
- Do not wait only 3 months for repeat FNA of AUS/FLUS nodules—this timing shows inferior diagnostic resolution compared to longer intervals 8
- Do not ignore ultrasound features—cytology alone is insufficient for risk stratification 2, 6
- Do not treat all Bethesda III nodules uniformly—cytomorphologic subtyping is essential 4
- Do not perform total thyroidectomy routinely—hemithyroidectomy is appropriate initial surgery given the favorable prognosis 3, 5
The presence of both nuclear atypia AND high-risk sonographic features creates a malignancy risk of 59-75%, justifying upfront surgery 2. In contrast, architectural atypia with benign/low-risk ultrasound can safely undergo surveillance, with the vast majority remaining stable 3.